.jpg "Aurinia Pharmaceuticals (NASDAQ: AUPH)")
In a report released yesterday, Douglas Miehm from RBC Capital maintained a Buy rating on Aurinia Pharmaceuticals (AUPH), with a price target of $11. The company’s shares opened today at $5.70.
Miehm has an average return of 5.9% when recommending Aurinia Pharmaceuticals.
According to TipRanks.com, Miehm is ranked #5091 out of 5229 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aurinia Pharmaceuticals with a $18 average price target, implying a 215.8% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.85 and a one-year low of $5.06. Currently, Aurinia Pharmaceuticals has an average volume of 451K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
